Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced stomach cancer: drug cocktails under trial

NCT ID NCT05329766

Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 5 times

Summary

This study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective options that shrink tumors and extend life.

Why investors are watching

Arcus Biosciences is running a phase 2 trial testing combination therapies, with and without chemotherapy, in people with advanced stomach, esophageal, and gastroesophageal junction cancers. For a small company, this readout matters because it could show whether its experimental drugs add benefit on top of standard chemotherapy in a hard-to-treat cancer. A clear signal could validate the company's pipeline, while a weak result would raise questions about the drugs' potential.

If it works: A positive result could position Arcus's combinations as a promising option for advanced upper gastrointestinal cancers, potentially attracting larger partners or advancing the drugs toward later-stage trials. That outcome would strengthen the company's pipeline and its standing among investors.

If it fails: A failure or delay could set the program back and hurt the company's prospects, since small companies often depend on a few key trials. Many phase 2 cancer trials do not meet their goals, so a negative readout is a real possibility.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

332 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Participants with histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma with life expectancy ≥3 months as assessed by the Investigator * Eastern cooperative oncology group (ECOG) Performance Score of 0-1 * At least one measurable target lesion per RECIST v1.1. * Adequate organ and marrow function * Able to provide an archival tumor sample that is representative of the cancer under investigation and suitable for central PD-L1 testing Key Exclusion Criteria: * Participants with underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational products hazardous * Only for Cohort A: Known Human Epidermal Growth Factor Receptor 2 (HER-2) positive tumor * Known untreated, symptomatic, or actively progressing central nervous system (brain) metastases. Participants with leptomeningeal metastases are excluded from enrollment. * Discontinued use of prior immune checkpoint therapy due to immune related adverse events; received prior treatment with an anti-TIGIT monoclonal antibody. * History of trauma or major surgery within 28 days prior to enrollment. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus digestive system cancer esophageal adenocarcinoma gastric adenocarcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal tract malignancies

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85054, United States

  • Research Site

    Los Angeles, California, 90033, United States

  • Research Site

    Santa Monica, California, 90024, United States

  • Research Site

    Derby, Connecticut, 06418, United States

  • Research Site

    Fort Myers, Florida, 33901, United States

  • Research Site

    Jacksonville, Florida, 32224, United States

  • Research Site

    St. Petersburg, Florida, 33705, United States

  • Research Site

    Boston, Massachusetts, 02109, United States

  • Research Site

    New York, New York, 10021-0005, United States

  • Research Site

    New York, New York, 10032, United States

  • Research Site

    Durham, North Carolina, 27710, United States

  • Research Site

    Columbus, Ohio, 43219, United States

  • Research Site

    Oklahoma City, Oklahoma, 73104, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Nashville, Tennessee, 37232, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Toronto, Canada

  • Research Site

    Las Condes, Chile

  • Research Site

    Recoleta, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Talca, Chile

  • Research Site

    Bordeaux, France

  • Research Site

    Brest, France

  • Research Site

    Caen, France

  • Research Site

    Lille, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

  • Research Site

    Montpellier, France

  • Research Site

    Plérin, France

  • Research Site

    Poitiers, France

  • Research Site

    Rouen, France

  • Research Site

    Toulouse, France

  • Research Site

    Villejuif, France

  • Research Site

    Belgrade, Serbia

  • Research Site

    Kamenitz, Serbia

  • Research Site

    Kragujevac, Serbia

  • Research Site

    Busan, South Korea

  • Research Site

    Daegu, South Korea

  • Research Site

    Hwasun, South Korea

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Suwon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.